Journey Medical Corp

DERM remains in early Stage 1 consolidation following a terminal decline and range-bound repair. A late-June breakout failed, evidenced by a Bullish Exhaustion candle, and price is overbought and facing resistance. This leads to a bearish medium-term bias, recommending selling into strength near the breakout region.

• ↑Q2 2026 revenue of $18.5M up 23% YoY; Adjusted EBITDA positive $2.9M
• ↑MROSI uptake reached ~36,000 prescriptions, contributing $8.1M revenue
• ↓Q2 net loss of $0.3M and negative earnings yield signal profit challenges